MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2022 financial results on Thursday, February 23, 2023, at 8:30 AM Eastern time.
Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Time | 8:30 A.M EST |
| Toll free (U.S.) | 1-833-630-1956 |
| International (U.S) | 1-412-317-1837 |
| Germany | 0800-6647650 |
| Israel | 1-80-9212373 |
| Access Code | Please ask to join into the ReWalk Robotics Ltd. call |
| Webcast (live and replay) | https://edge.media-server.com/mmc/p/z32t5emd under the ‘Investors’ section'. |
The archived webcast will be available via the following link https://edge.media-server.com/mmc/p/z32t5emd or through the 'Investors' section' on www.rewalk.com.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.
Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
T: +1 508-281-7274
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.54 |
| Daily Change: | -0.08 -4.94 |
| Daily Volume: | 258,027 |
| Market Cap: | US$16.370M |
January 08, 2025 January 07, 2025 November 12, 2024 October 24, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
